Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock

被引:122
作者
Varghese, Julie M. [2 ]
Roberts, Jason A. [1 ,2 ,3 ]
Lipman, Jeffrey [1 ,2 ]
机构
[1] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld 4029, Australia
[2] Univ Queensland, Royal Brisbane & Womens Hosp, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld 4029, Australia
[3] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld 4029, Australia
基金
英国医学研究理事会;
关键词
Pharmacokinetics; Pharmacodynamics; Volume of distribution; Clearance; Renal failure; Renal replacement therapy; INTENSIVE-CARE-UNIT; VENTILATOR-ASSOCIATED PNEUMONIA; TARGET SITE PENETRATION; CLINICAL PHARMACOKINETICS; CONTINUOUS-INFUSION; CIPROFLOXACIN PHARMACOKINETICS; INTRAPULMONARY CONCENTRATIONS; INTRAVENOUS CIPROFLOXACIN; CREATININE CLEARANCE; PEAK CONCENTRATION;
D O I
10.1016/j.ccc.2010.09.006
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD) are important considerations, particularly in critically ill patients with severe sepsis and septic shock. The pathophysiologic changes that occur in these conditions can have a major effect on pharmacokinetic parameters, which in turn could result in failure to achieve pharmacodynamic targets for antimicrobials thus adversely affecting clinical outcome. This paper discusses the pathophysiologic changes that occur during severe sepsis and septic shock and the consequent effects on antimicrobial PK and PD. The effect of PK/PD on specific antimicrobial classes is discussed and a rational framework for antimicrobial dosing is provided. Knowledge of PK/PD properties of antimicrobials can be used to personalize dosing regimens not only to maximize antimicrobial activity but also to minimize toxicity and reduce the development of antimicrobial resistance.
引用
收藏
页码:19 / +
页数:17
相关论文
共 89 条
[1]  
Alet Patrice, 1999, Clin Microbiol Infect, V5, P213
[2]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[3]  
[Anonymous], DEATHS FINAL DATA 20
[4]   ALTERED AMINOGLYCOSIDE PHARMACOKINETICS IN THE CRITICALLY ILL [J].
BECKHOUSE, MJ ;
WHYTE, IM ;
BYTH, PL ;
NAPIER, JC ;
SMITH, AJ .
ANAESTHESIA AND INTENSIVE CARE, 1988, 16 (04) :418-422
[5]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[6]   Science, medicine, and the future - Pathogenesis of sepsis: new concepts and implications for future treatment [J].
Bochud, PY ;
Calandra, T .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7383) :262-266
[7]   THE PATHOGENESIS OF SEPSIS [J].
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :457-469
[8]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[9]   Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia [J].
Boselli, E ;
Breilh, D ;
Rimmelé, T ;
Djabarouti, S ;
Toutain, A ;
Chassard, D ;
Saux, MC ;
Allaouchiche, B .
CRITICAL CARE MEDICINE, 2005, 33 (07) :1529-1533
[10]   Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia [J].
Boselli, E ;
Breilh, D ;
Duflo, F ;
Saux, MC ;
Debon, R ;
Chassard, D ;
Allaouchiche, B .
CRITICAL CARE MEDICINE, 2003, 31 (08) :2102-2106